略過巡覽連結Home > About Us
Mission & Objectives

The Development Center for Biotechnology (DCB) of Taiwan is a nonprofit organization founded in 1984, based on government grants and private donations. DCB's mission is to accelerate the development of Taiwan's biotech-pharma industry, by accomplishing the main objectives of building infrastructures, developing key technologies, promoting cooperation and industrialization, and training talented workforces, in coordination with governmental, industrial, and academic institutions.

DCB is a value-adding partner for biotech-pharma companies of Taiwan. It plays the role of a "second-runner" in the relay-race of new drug development in Taiwan, by adding values to drug leads licensed from the "first-runner" - local or foreign companies, research institutes and universities. DCB adds values through preclinical development efforts ranging from medicinal chemistry and lead optimization to pharmacology and safety studies, which eventually lead to IND-filings and approvals. The resulting drug candidates are then licensed out to the "next-runner" in the relay - companies in the biotech-pharma industry - for clinical trials and the ultimate goal of product commercialization. In response to customer needs, DCB also facilitates technology cooperation and product commercialization processes, by employing suitable business models covering: patent licensing, technology transfer, strategic alliance, research collaboration, contract service, and spin-out venture. The objective is to help create win-win opportunities for partnership stakeholders with optimized coordination and integration of resources in Taiwan, and eventually, to help domestic companies expand business in the global market.

Positioning & Vision

In line with the government’s biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D and Integrated Service Center for Biopharmaceuticals" to provide integrated services ranging from R&D to business development. This role is to be fulfilled by devoting concerted efforts on preclinical developments of protein, small-molecule and botanical drug leads, and setting top priorities on obtaining Investigational New Drug (IND) approvals from domestic and foreign regulatory agencies.

DCB is dedicated to realizing the vision of becoming a "Leading Organization for Resource Integration, Value Creation and Biopharmaceutical Development". This is to be achieved by building world-caliber infrastructures, establishing key technologies for preclinical development, and fostering growths of highly-trained technology and business teams. In the long run, these efforts should lead to success stories of new drug development in Taiwan, and result in vigorous growth and prosperity for Taiwan's biotech-pharma industry.